{"id":9208,"date":"2025-11-15T09:21:42","date_gmt":"2025-11-15T06:21:42","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9208"},"modified":"2025-11-15T09:21:42","modified_gmt":"2025-11-15T06:21:42","slug":"first-oral-needle-free-pcsk9-achieves-60-ldl-reduction-matching-injectables-aha-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/first-oral-needle-free-pcsk9-achieves-60-ldl-reduction-matching-injectables-aha-2025\/","title":{"rendered":"First Oral, Needle-Free PCSK9 Achieves 60% LDL Reduction\u2014Matching Injectables: AHA 2025"},"content":{"rendered":"<div>First Oral, Needle-Free PCSK9 Achieves 60% LDL Reduction\u2014Matching Injectables: AHA 2025<\/div>\n<div><\/div>\n<div>Source:<\/div>\n<div>Source: AHA Newsroom, Nov 10, 2025 \u2014 AHA Scientific Sessions 2025<\/div>\n<div><\/div>\n<div>Keynotes :<\/div>\n<div><span> 1. New oral PCSK9 inhibitor (Enlicitide decanoate) lowers LDL up to 60%\u2014first PCSK9 option without injections.<\/span><\/div>\n<div><span> 2. CORALreef Lipids trial: ~3,000 high-risk patients (on statins or statin-intolerant), 24 weeks, 14 countries.<\/span><\/div>\n<div><span> 3. Results:<\/span><\/div>\n<div><span> \u2022 LDL \u2193 up to 60%<\/span><\/div>\n<div><span> \u2022 ApoB \u2193 50%<\/span><\/div>\n<div><span> \u2022 Lp(a) \u2193 28%<\/span><\/div>\n<div><span> 4. Safety: Side-effects similar to placebo; well tolerated.<\/span><\/div>\n<div><span> 5. Effectiveness matches injectable PCSK9 inhibitors, offering a needle-free alternative.<\/span><\/div>\n<div><span> 6. Regulatory plan: Merck will submit data from CORALreef Lipids, HeHF, and AddOn to FDA and global agencies.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/professional.heart.org\/en\/meetings\/scientific-sessions\/\">https:\/\/professional.heart.org\/en\/meetings\/scientific-sessions\/<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>First Oral, Needle-Free PCSK9 Achieves 60% LDL Reduction\u2014Matching Injectables: AHA 2025 Source: Source: AHA Newsroom, Nov 10, 2025 \u2014 AHA Scientific Sessions 2025 Keynotes : 1. New oral PCSK9 inhibitor (Enlicitide decanoate) lowers LDL up to 60%\u2014first PCSK9 option without injections. 2. CORALreef Lipids trial: ~3,000 high-risk patients (on statins or statin-intolerant), 24 weeks, 14 [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9208","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9208"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9208\/revisions"}],"predecessor-version":[{"id":9209,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9208\/revisions\/9209"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}